Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.
Novel approaches including gene editing are creeping towards approval.
Will upping the dose and changing the primary endpoint pay off?
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
The company reports decent data with its Oxbryta follow-on, but still has much to prove.